WDR62 and prostate cancer: We note that WDR62 was previously characterized as a biomarker of resistance to AR targeted therapies in models of neuroendocrine prostate cancer (NEPC) and in NEPC patient samples however to our knowledge WDR62 has not been previously implicated as a driver of prostate cancer adenocarcinoma38.